{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:08:44Z","timestamp":1791464924380,"version":"4.3.4"},"reference-count":96,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2014,6,4]],"date-time":"2014-06-04T00:00:00Z","timestamp":1401840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Brain tumor-related epilepsy (BTE) is common in low- and high-grade gliomas. The risk of seizures varies between 60% and 100% among low-grade gliomas and between 40% and 60% in glioblastomas. The presence of seizures in patients with brain tumors implies favorable and unfavorable factors. New-onset seizures represent an early warning sign for the presence of a brain tumor and count as a good prognostic factor for survival. Recurrence or worsening of seizures during the course of disease may signal tumor progression. Each of the modalities for tumor control (i.e., surgery, radiotherapy, chemotherapy) contributes to seizure control. Nevertheless, one third of BTE shows pharmacoresistance to antiepileptic drugs (AEDs) and may severely impair the burden of living with a brain tumor. For symptomatic therapy of BTE, seizure type and individual patient factors determine the appropriate AED. Randomized controlled trials in partial epilepsy in adults to which type BTE belongs and additional studies in gliomas indicate that levetiracetam is the agent of choice, followed by valproic acid (VPA). In the case of recurring seizures, combining these two drugs (polytherapy) seems effective and possibly synergistic. If either one is not effective or not well tolerated, lacosamide, lamotrigine, or zonisamide are additional options. A new and exciting insight is the potential contribution of VPA to prolonged survival, particularly in glioblastomas. A practice guideline on symptomatic medical management including dose schedules of AEDs is supplied.<\/jats:p>","DOI":"10.1634\/theoncologist.2014-0060","type":"journal-article","created":{"date-parts":[[2014,6,5]],"date-time":"2014-06-05T02:08:13Z","timestamp":1401934093000},"page":"751-759","source":"Crossref","is-referenced-by-count":230,"title":["Seizure Prognosis in Brain Tumors: New Insights and Evidence-Based Management"],"prefix":"10.1093","volume":"19","author":[{"given":"Charles J.","family":"Vecht","sequence":"first","affiliation":[{"name":"Service Neurologie Mazarin, GH Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France;"},{"name":"Department of Neurology, Medical Center The Hague, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Kerkhof","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Center The Hague, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Duran-Pena","sequence":"additional","affiliation":[{"name":"Service Neurologie Mazarin, GH Piti\u00e9-Salp\u00eatri\u00e8re, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2014,6,4]]},"reference":[{"key":"2021122309081767000_B1","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1212\/WNL.0b013e3181f96282","article-title":"IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas","volume":"75","author":"Houillier","year":"2010","journal-title":"Neurology"},{"key":"2021122309081767000_B2","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.2353\/ajpath.2009.080958","article-title":"IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas","volume":"174","author":"Watanabe","year":"2009","journal-title":"Am J Pathol"},{"key":"2021122309081767000_B3","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1212\/WNL.0b013e3181c34ace","article-title":"IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide","volume":"73","author":"Dubbink","year":"2009","journal-title":"Neurology"},{"key":"2021122309081767000_B4","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.seizure.2011.12.007","article-title":"IDH1\/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom","volume":"21","author":"Stockhammer","year":"2012","journal-title":"Seizure"},{"key":"2021122309081767000_B5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1212\/WNL.0b013e318266fa89","article-title":"Glutamate is associated with a higher risk of seizures in patients with gliomas","volume":"79","author":"Yuen","year":"2012","journal-title":"Neurology"},{"key":"2021122309081767000_B6","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/neuonc\/nos338","article-title":"Glutamine synthetase expression as a valuable marker of epilepsy and longer survival in newly diagnosed glioblastoma multiforme","volume":"15","author":"Rosati","year":"2013","journal-title":"Neuro Oncol"},{"key":"2021122309081767000_B7","doi-asserted-by":"crossref","first-page":"9866","DOI":"10.1523\/JNEUROSCI.2761-07.2007","article-title":"Perturbed chloride homeostasis and GABAergic signaling in human temporal lobe epilepsy","volume":"27","author":"Huberfeld","year":"2007","journal-title":"J Neurosci"},{"issue":"suppl 9","key":"2021122309081767000_B8","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/epi.12440","article-title":"Tumoral epileptogenicity: How does it happen?","volume":"54","author":"Pallud","year":"2013","journal-title":"Epilepsia"},{"key":"2021122309081767000_B9","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.seizure.2012.05.014","article-title":"Seizure prognosis of patients with low-grade tumors","volume":"21","author":"Kahlenberg","year":"2012","journal-title":"Seizure"},{"issue":"suppl 4","key":"2021122309081767000_B10","doi-asserted-by":"crossref","first-page":"iv55","DOI":"10.1093\/neuonc\/nos199","article-title":"Seizures in low-grade gliomas: Natural history, pathogenesis, and outcome after treatments","volume":"14","author":"Rud\u00e0","year":"2012","journal-title":"Neuro Oncol"},{"key":"2021122309081767000_B11","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1093\/neuonc\/not057","article-title":"Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme","volume":"15","author":"Kerkhof","year":"2013","journal-title":"Neuro Oncol"},{"key":"2021122309081767000_B12","first-page":"391","article-title":"Pharmacotherapy of epileptic seizures in glioma patients: Who, when, why and how long?","volume":"28","author":"Wick","year":"2005","journal-title":"Onkologie"},{"key":"2021122309081767000_B13","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1007\/s00415-009-5156-9","article-title":"Efficacy of anti-epileptic drugs in patients with gliomas and seizures","volume":"256","author":"Van Breemen","year":"2009","journal-title":"J Neurol"},{"key":"2021122309081767000_B14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3171\/JNS\/2008\/108\/2\/0227","article-title":"Seizure characteristics and control following resection in 332 patients with low-grade gliomas","volume":"108","author":"Chang","year":"2008","journal-title":"J Neurosurg"},{"key":"2021122309081767000_B15","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3171\/2009.2.JNS081132","article-title":"Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. Clinical article","volume":"111","author":"Chaichana","year":"2009","journal-title":"J Neurosurg"},{"key":"2021122309081767000_B16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1212\/01.wnl.0000168903.09277.8f","article-title":"Epileptic seizures during follow-up of patients treated for primary brain tumors","volume":"65","author":"Hildebrand","year":"2005","journal-title":"Neurology"},{"key":"2021122309081767000_B17","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1093\/neuonc\/nor205","article-title":"Seizure characteristics and outcomes in 508 Chinese adult patients undergoing primary resection of low-grade gliomas: A clinicopathological study","volume":"14","author":"You","year":"2012","journal-title":"Neuro Oncol"},{"key":"2021122309081767000_B18","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/neuonc\/not109","article-title":"Seizure control following radiotherapy in patients with diffuse gliomas: A retrospective study","volume":"15","author":"Rud\u00e0","year":"2013","journal-title":"Neuro Oncol"},{"key":"2021122309081767000_B19","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1200\/JCO.2002.08.121","article-title":"Prognostic factors for survival in adult patients with cerebral low-grade glioma","volume":"20","author":"Pignatti","year":"2002","journal-title":"J Clin Oncol"},{"key":"2021122309081767000_B20","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1227\/NEU.0b013e31823c3a30","article-title":"Extent of surgical resection predicts seizure freedom in low-grade temporal lobe brain tumors","volume":"70","author":"Englot","year":"2012","journal-title":"Neurosurgery"},{"key":"2021122309081767000_B21","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00701-002-0941-6","article-title":"Medically intractable epilepsy from insular low-grade gliomas: Improvement after an extended lesionectomy","volume":"144","author":"Duffau","year":"2002","journal-title":"Acta Neurochir (Wien)"},{"key":"2021122309081767000_B22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/brain\/awt345","article-title":"Epileptic seizures in diffuse low-grade gliomas in adults","volume":"137","author":"Pallud","year":"2014","journal-title":"Brain"},{"key":"2021122309081767000_B23","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00701-009-0232-6","article-title":"Re-operation is a safe and effective therapeutic strategy in recurrent WHO grade II gliomas within eloquent areas","volume":"151","author":"Martino","year":"2009","journal-title":"Acta Neurochir (Wien)"},{"key":"2021122309081767000_B24","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1046\/j.1528-1157.2003.56102.x","article-title":"The spectrum of long-term epilepsy-associated tumors: Long-term seizure and tumor outcome and neurosurgical aspects","volume":"44","author":"Luyken","year":"2003","journal-title":"Epilepsia"},{"key":"2021122309081767000_B25","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1750-3639.2012.00582.x","article-title":"Long-term epilepsy-associated tumors","volume":"22","author":"Thom","year":"2012","journal-title":"Brain Pathol"},{"key":"2021122309081767000_B26","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1528-1167.2011.03269.x","article-title":"Factors associated with seizure freedom in the surgical resection of glioneuronal tumors","volume":"53","author":"Englot","year":"2012","journal-title":"Epilepsia"},{"key":"2021122309081767000_B27","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1227\/NEU.0b013e3182500a4c","article-title":"Long-term seizure control outcomes after resection of gangliogliomas","volume":"70","author":"Southwell","year":"2012","journal-title":"Neurosurgery"},{"key":"2021122309081767000_B28","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1179\/016164107X223566","article-title":"Additional hippocampectomy in the surgical management of intractable temporal lobe epilepsy associated with glioneuronal tumor","volume":"29","author":"Morioka","year":"2007","journal-title":"Neurol Res"},{"key":"2021122309081767000_B29","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s00701-011-1259-z","article-title":"Seizure outcome with surgical management of epileptogenic ganglioglioma: A study of 55 patients","volume":"154","author":"Hu","year":"2012","journal-title":"Acta Neurochir (Wien)"},{"key":"2021122309081767000_B30","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0140-6736(05)67070-5","article-title":"Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomised trial","volume":"366","author":"Van den Bent","year":"2005","journal-title":"Lancet"},{"key":"2021122309081767000_B31","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/annonc\/mdg502","article-title":"Temozolomide chemotherapy for progressive low-grade glioma: Clinical benefits and radiological response","volume":"14","author":"Pace","year":"2003","journal-title":"Ann Oncol"},{"key":"2021122309081767000_B32","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/annonc\/mdg371","article-title":"Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas","volume":"14","author":"Brada","year":"2003","journal-title":"Ann Oncol"},{"key":"2021122309081767000_B33","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1212\/01.wnl.0000262034.26310.a2","article-title":"Temozolomide for low-grade gliomas: Predictive impact of 1p\/19q loss on response and outcome","volume":"68","author":"Kaloshi","year":"2007","journal-title":"Neurology"},{"key":"2021122309081767000_B34","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.3171\/2010.12.JNS101602","article-title":"Impact of temozolomide chemotherapy on seizure frequency in patients with low-grade gliomas","volume":"114","author":"Sherman","year":"2011","journal-title":"J Neurosurg"},{"key":"2021122309081767000_B35","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.3171\/2009.6.FOCUS09102","article-title":"Epilepsy and insular grade II gliomas: An interdisciplinary point of view from a retrospective monocentric series of 46 cases","volume":"27","author":"Taillandier","year":"2009","journal-title":"Neurosurg Focus"},{"key":"2021122309081767000_B36","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1474-4422(03)00435-6","article-title":"Interactions between antiepileptic and chemotherapeutic drugs","volume":"2","author":"Vecht","year":"2003","journal-title":"Lancet Neurol"},{"key":"2021122309081767000_B37","first-page":"15","article-title":"Spectrum of side effects of anticonvulsants in patients with brain tumours","volume":"2","author":"B\u00e9nit","year":"2012","journal-title":"EANO Magazine"},{"key":"2021122309081767000_B38","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"2021122309081767000_B39","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1212\/WNL.54.10.1886","article-title":"Practice parameter: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors","volume":"54","author":"Glantz","year":"2000","journal-title":"Neurology"},{"key":"2021122309081767000_B40","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1468-1331.2010.03151.x","article-title":"Guidelines on management of low-grade gliomas: Report of an EFNS-EANO Task Force","volume":"17","author":"Soffietti","year":"2010","journal-title":"Eur J Neurol"},{"key":"2021122309081767000_B41","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-0404.2009.01226.x","article-title":"Efficacy and tolerability of zonisamide as add-on in brain tumor-related epilepsy: Preliminary report","volume":"120","author":"Maschio","year":"2009","journal-title":"Acta Neurol Scand"},{"key":"2021122309081767000_B42","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S1059-1311(03)00096-7","article-title":"Levetiracetam: Preliminary experience in patients with primary brain tumours","volume":"12","author":"Wagner","year":"2003","journal-title":"Seizure"},{"key":"2021122309081767000_B43","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11060-006-9162-9","article-title":"Levetiracetam therapy in patients with brain tumour and epilepsy","volume":"80","author":"Maschio","year":"2006","journal-title":"J Neurooncol"},{"key":"2021122309081767000_B44","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11060-010-0460-x","article-title":"Levetiracetam monotherapy in patients with brain tumor-related epilepsy: Seizure control, safety, and quality of life","volume":"104","author":"Maschio","year":"2011","journal-title":"J Neurooncol"},{"key":"2021122309081767000_B45","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11060-008-9781-4","article-title":"Safety and feasibility of switching from phenytoin to levetiracetam monotherapy for glioma-related seizure control following craniotomy: A randomized phase II pilot study","volume":"93","author":"Lim","year":"2009","journal-title":"J Neurooncol"},{"key":"2021122309081767000_B46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11060-005-9070-4","article-title":"Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients","volume":"78","author":"Newton","year":"2006","journal-title":"J Neurooncol"},{"key":"2021122309081767000_B47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/archneurol.2009.335","article-title":"Efficacy and safety of levetiracetam in patients with glioma: A clinical prospective study","volume":"67","author":"Rosati","year":"2010","journal-title":"Arch Neurol"},{"key":"2021122309081767000_B48","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00701-011-1144-9","article-title":"Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: The HELLO trial","volume":"154","author":"B\u00e4hr","year":"2012","journal-title":"Acta Neurochir (Wien)"},{"key":"2021122309081767000_B49","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/neuonc\/nos288","article-title":"Levetiracetam improves verbal memory in high-grade glioma patients","volume":"15","author":"De Groot","year":"2013","journal-title":"Neuro Oncol"},{"key":"2021122309081767000_B50","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/bcp.12083","article-title":"Comparative efficacy and tolerability of anti-epileptic drugs for refractory focal epilepsy: Systematic review and network meta-analysis reveals the need for long term comparator trials","volume":"76","author":"Bodalia","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"2021122309081767000_B51","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s11060-007-9373-8","article-title":"Retrospective analysis of the efficacy and tolerability of levetiracetam in patients with metastatic brain tumors","volume":"84","author":"Newton","year":"2007","journal-title":"J Neurooncol"},{"key":"2021122309081767000_B52","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11060-009-0069-0","article-title":"Antiepileptics in brain metastases: Safety, efficacy and impact on life expectancy","volume":"98","author":"Maschio","year":"2010","journal-title":"J Neurooncol"},{"key":"2021122309081767000_B53","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1212\/WNL.0b013e31822f02e1","article-title":"Prolonged survival with valproic acid use in the EORTC\/NCIC temozolomide trial for glioblastoma","volume":"77","author":"Weller","year":"2011","journal-title":"Neurology"},{"key":"2021122309081767000_B54","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s11060-012-0836-1","article-title":"Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy","volume":"108","author":"Sim\u00f3","year":"2012","journal-title":"J Neurooncol"},{"key":"2021122309081767000_B55","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/01.wnf.0000159956.87511.67","article-title":"Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy","volume":"28","author":"Otoul","year":"2005","journal-title":"Clin Neuropharmacol"},{"key":"2021122309081767000_B56","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s11060-007-9430-3","article-title":"Outcome and tolerability of topiramate in brain tumor associated epilepsy","volume":"86","author":"Maschio","year":"2008","journal-title":"J Neurooncol"},{"key":"2021122309081767000_B57","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00023210-200923040-00006","article-title":"Efficacy of topiramate in adult patients with symptomatic epilepsy: An open-label, long-term, retrospective observation","volume":"23","author":"Lu","year":"2009","journal-title":"CNS Drugs"},{"key":"2021122309081767000_B58","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s11060-006-9229-7","article-title":"Prevention of early postoperative seizures in patients with primary brain tumors: Preliminary experience with oxcarbazepine","volume":"81","author":"Mauro","year":"2007","journal-title":"J Neurooncol"},{"key":"2021122309081767000_B59","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1756-9966-28-60","article-title":"The role side effects play in the choice of antiepileptic therapy in brain tumor-related epilepsy: A comparative study on traditional antiepileptic drugs versus oxcarbazepine","volume":"28","author":"Maschio","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"key":"2021122309081767000_B60","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s11060-011-0689-z","article-title":"Oxcarbazepine monotherapy in patients with brain tumor-related epilepsy: Open-label pilot study for assessing the efficacy, tolerability and impact on quality of life","volume":"106","author":"Maschio","year":"2012","journal-title":"J Neurooncol"},{"key":"2021122309081767000_B61","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1007\/s00415-011-6132-8","article-title":"Lacosamide as add-on in brain tumor-related epilepsy: Preliminary report on efficacy and tolerability","volume":"258","author":"Maschio","year":"2011","journal-title":"J Neurol"},{"key":"2021122309081767000_B62","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.3171\/2013.1.JNS12397","article-title":"Retrospective analysis of the tolerability and activity of lacosamide in patients with brain tumors: Clinical article","volume":"118","author":"Saria","year":"2013","journal-title":"J Neurosurg"},{"key":"2021122309081767000_B63","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/neuonc\/not170","article-title":"Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study","volume":"16","author":"Rossetti","year":"2014","journal-title":"Neuro Oncol"},{"issue":"suppl 8","key":"2021122309081767000_B64","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1528-1167.2009.02238.x","article-title":"Rational polytherapy","volume":"50","author":"French","year":"2009","journal-title":"Epilepsia"},{"key":"2021122309081767000_B65","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.seizure.2011.01.004","article-title":"Combining antiepileptic drugs\u2014Rational polytherapy?","volume":"20","author":"Brodie","year":"2011","journal-title":"Seizure"},{"key":"2021122309081767000_B66","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1227\/NEU.0b013e31820c3419","article-title":"Seizures and the natural history of World Health Organization Grade II gliomas: A review","volume":"68","author":"Smits","year":"2011","journal-title":"Neurosurgery"},{"key":"2021122309081767000_B67","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0306-4522(02)00992-2","article-title":"Expression and cellular distribution of multidrug transporter proteins in two major causes of medically intractable epilepsy: Focal cortical dysplasia and glioneuronal tumors","volume":"118","author":"Aronica","year":"2003","journal-title":"Neuroscience"},{"key":"2021122309081767000_B68","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s11060-012-0946-9","article-title":"Multidrug resistance proteins expression in glioma patients with epilepsy","volume":"110","author":"Calatozzolo","year":"2012","journal-title":"J Neurooncol"},{"key":"2021122309081767000_B69","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1684\/j.1950-6945.2005.tb00145.x","article-title":"Mechanisms of drug resistance","volume":"7","author":"Loscher","year":"2005","journal-title":"Epileptic Disord"},{"key":"2021122309081767000_B70","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1111\/j.1528-1167.2011.03140.x","article-title":"In vitro transport profile of carbamazepine, oxcarbazepine, eslicarbazepine acetate, and their active metabolites by human P-glycoprotein","volume":"52","author":"Zhang","year":"2011","journal-title":"Epilepsia"},{"key":"2021122309081767000_B71","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0920-1211(96)01007-8","article-title":"Lamotrigine substitution study: Evidence for synergism with sodium valproate? 105 Study Group","volume":"26","author":"Brodie","year":"1997","journal-title":"Epilepsy Res"},{"key":"2021122309081767000_B72","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1212\/WNL.0b013e31823ed0dd","article-title":"Comparative efficacy of combination drug therapy in refractory epilepsy","volume":"78","author":"Poolos","year":"2012","journal-title":"Neurology"},{"key":"2021122309081767000_B73","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.seizure.2006.05.001","article-title":"Predicting drug-resistant patients who respond to add-on therapy with levetiracetam","volume":"15","author":"Kinirons","year":"2006","journal-title":"Seizure"},{"key":"2021122309081767000_B74","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/1756285608094212","article-title":"Is levetiracetam different from other antiepileptic drugs? Levetiracetam and its cellular mechanism of action in epilepsy revisited","volume":"1","author":"Surges","year":"2008","journal-title":"Ther Adv Neurol Disord"},{"key":"2021122309081767000_B75","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.seizure.2009.06.009","article-title":"Isobolographic characterization of the anticonvulsant interaction profiles of levetiracetam in combination with clonazepam, ethosuximide, phenobarbital and valproate in the mouse pentylenetetrazole-induced seizure model","volume":"18","author":"Dudra-Jastrzebska","year":"2009","journal-title":"Seizure"},{"key":"2021122309081767000_B76","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eplepsyres.2009.06.003","article-title":"Isobolographic characterization of interactions of levetiracetam with the various antiepileptic drugs in the mouse 6 Hz psychomotor seizure model","volume":"86","author":"Wojda","year":"2009","journal-title":"Epilepsy Res"},{"key":"2021122309081767000_B77","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1474-4422(04)00680-5","article-title":"Cognitive deficits in adult patients with brain tumours","volume":"3","author":"Taphoorn","year":"2004","journal-title":"Lancet Neurol"},{"key":"2021122309081767000_B78","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-004-2338-2","article-title":"P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy","volume":"72","author":"Oberndorfer","year":"2005","journal-title":"J Neurooncol"},{"key":"2021122309081767000_B79","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3171\/2012.10.JNS12169","article-title":"Impact of particular antiepileptic drugs on the survival of patients with glioblastoma multiforme","volume":"118","author":"Guthrie","year":"2013","journal-title":"J Neurosurg"},{"key":"2021122309081767000_B80","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.ijrobp.2013.02.012","article-title":"Valproic acid use during radiation therapy for glioblastoma associated with improved survival","volume":"86","author":"Barker","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2021122309081767000_B81","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s00381-012-1997-0","article-title":"Survival of children with malignant brain tumors receiving valproate: A retrospective study","volume":"29","author":"Felix","year":"2013","journal-title":"Childs Nerv Syst"},{"key":"2021122309081767000_B82","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s11060-007-9402-7","article-title":"Valproic acid induces p21 and topoisomerase-II (alpha\/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines","volume":"85","author":"Das","year":"2007","journal-title":"J Neurooncol"},{"key":"2021122309081767000_B83","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1007\/s11064-011-0554-7","article-title":"Valproic acid induced differentiation and potentiated efficacy of taxol and nanotaxol for controlling growth of human glioblastoma LN18 and T98G cells","volume":"36","author":"Roy Choudhury","year":"2011","journal-title":"Neurochem Res"},{"key":"2021122309081767000_B84","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1111\/j.1349-7006.2009.01237.x","article-title":"Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors","volume":"100","author":"Fujiwara","year":"2009","journal-title":"Cancer Sci"},{"key":"2021122309081767000_B85","doi-asserted-by":"crossref","first-page":"793","DOI":"10.2146\/ajhp090247","article-title":"Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma","volume":"67","author":"Kavanaugh","year":"2010","journal-title":"Am J Health Syst Pharm"},{"key":"2021122309081767000_B86","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1183\/09031936.00037310","article-title":"Valproate-doxorubicin: Promising therapy for progressing mesothelioma. A phase II study","volume":"37","author":"Scherpereel","year":"2011","journal-title":"Eur Respir J"},{"key":"2021122309081767000_B87","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.leukres.2011.02.021","article-title":"Hematologic improvement and response in elderly AML\/RAEB patients treated with valproic acid and low-dose Ara-C","volume":"35","author":"Corsetti","year":"2011","journal-title":"Leuk Res"},{"key":"2021122309081767000_B88","doi-asserted-by":"crossref","first-page":"S540","DOI":"10.1007\/s12032-010-9700-3","article-title":"A double-blind, placebo-controlled, randomized phase III trial of chemotherapy plus epigenetic therapy with hydralazine valproate for advanced cervical cancer. Preliminary results","volume":"28","author":"Coronel","year":"2011","journal-title":"Med Oncol"},{"key":"2021122309081767000_B89","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1158\/1078-0432.CCR-08-0643","article-title":"Postradiation sensitization of the histone deacetylase inhibitor valproic acid","volume":"14","author":"Chinnaiyan","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2021122309081767000_B90","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1038\/onc.2011.614","article-title":"Histone deacetylase inhibitors sensitize glioblastoma cells to TRAIL-induced apoptosis by c-myc-mediated downregulation of cFLIP","volume":"31","author":"Bangert","year":"2012","journal-title":"Oncogene"},{"key":"2021122309081767000_B91","doi-asserted-by":"crossref","first-page":"737","DOI":"10.4149\/neo_2012_093","article-title":"Neuroblastoma stem cells\u2014Mechanisms of chemoresistance and histone deacetylase inhibitors","volume":"59","author":"Khalil","year":"2012","journal-title":"Neoplasma"},{"key":"2021122309081767000_B92","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1093\/neuonc\/noq044","article-title":"Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide","volume":"12","author":"Bobustuc","year":"2010","journal-title":"Neuro Oncol"},{"key":"2021122309081767000_B93","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1212\/WNL.0b013e3181bbfeca","article-title":"Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma","volume":"73","author":"Jaeckle","year":"2009","journal-title":"Neurology"},{"key":"2021122309081767000_B94","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1528-1167.2011.03335.x","article-title":"Antiepileptic drug selection for people with HIV\/AIDS: Evidence-based guidelines from the ILAE and AAN","volume":"53","author":"Birbeck","year":"2012","journal-title":"Epilepsia"},{"key":"2021122309081767000_B95","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as adjunctive therapy for partial-onset seizures: A randomized controlled trial","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"key":"2021122309081767000_B96","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/S1474-4422(12)70105-9","article-title":"Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: A phase 3, randomised, double-blind, non-inferiority trial","volume":"11","author":"Baulac","year":"2012","journal-title":"Lancet Neurol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2014-0060","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2014-0060","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/7\/751\/41862372\/oncolo_19_7_751.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/19\/7\/751\/41862372\/oncolo_19_7_751.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T09:41:40Z","timestamp":1716802900000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/19\/7\/751\/6399337"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,4]]},"references-count":96,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,6,4]]},"published-print":{"date-parts":[[2014,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2014-0060","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,7,1]]},"published":{"date-parts":[[2014,6,4]]}}}